¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antigen tolerance"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • complete antigen
    ¿ÏÀüÇ׿ø
  • conjugated antigen
    Á¢ÇÕÇ׿ø, °áÇÕÇ׿ø
  • carcinoembryonic antigen
    ¾Ï¹è¾ÆÇ׿ø
  • core antigen
    ÇÙ½ÉÇ׿ø
  • cross-reacting antigen
    ±³Â÷¹ÝÀÀÇ׿ø
  • diphasic antigen
    ÀÌ»ó(ì£ßÓ)Ç׿ø
  • early antigen
    ÃʱâÇ׿ø
  • excretory-secretory antigen
    ¹è¼³ºÐºñÇ׿ø
  • egg antigen
    Ãæ¶õÇ׿ø
  • envelope antigen
    ¿ÜÇÇÇ׿ø
  • environmental antigen
    ȯ°æÇ׿ø
  • epithelial membrane antigen
    »óÇǸ·Ç׿ø
  • fimbrial antigen
    °¡´ÂÅÐÇ׿ø
  • flagellar antigen
    Æí¸ðÇ׿ø
  • formalinized antigen
    Æ÷¸£¸»¸°Ã³¸®Ç׿ø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • antigen binding capacity
    Ç׿ø°áÇÕ´É
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen diffusion constant
    Ç׿øÈ®»ê»ó¼ö
  • antigen excess zone
    Ç׿ø°úÀ×±¸¿ª
  • antigen-antibody complex
    Ç׿øÇ×üº¹ÇÕü
  • antigen-antibody interaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-presenting cell
    Ç׿øÀü´Þ¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
  • avidin-antigen conjugate
    ¾ÆºñµòÇ׿øÁ¢ÇÕü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Chido (Ch") antigen
    Chido(Ch") Ç׿ø
  • D antigen
    D Ç׿ø
  • D antigen
    DÇ׿ø
  • D-related antigen
    D-°ü·ÃÇ׿ø
  • DP antigen
    DPÇ׿ø
  • DQ antigen
    DQÇ׿ø
  • DR antigen
    DRÇ׿ø
  • Diego antigen
    µð¿¡°íÇ׿ø
  • EB nuclear antigen(EBNA0
    EB ¹ÙÀÌ·¯½º ÇÙÇ׿ø
  • EB nuclear antigen (EBNA)
    EB¹ÙÀÌ·¯½º ÇÙÇ׿ø
  • EBV capsid antigen
    EB¹ÙÀÌ·¯½º ĸ½Ãµå Ç׿ø
  • EBV capsid antigen (VCA)
    EB¹ÙÀÌ·¯½º ĸ½ÃµåÇ׿ø
  • EBV membrane antigen
    EB¹ÙÀÌ·¯½º ¸·Ç׿ø
  • EBV membrane antigen (MA)
    EB¹ÙÀÌ·¯½º ¸·Ç׿ø
  • Forssman antigen
    Æ÷½º¸¸Ç׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • induction, tolerance
    °ü¿ëÀ¯¹ß (¸é¿ª)
  • infectious tolerance
    Àü´Þ¼º ¸é¿ª°ü¿ë
  • insulin tolerance
    Àν¶¸°³»¼º.
  • insulin tolerance test
    Àν¶¸°³»¼º½ÃÇè
  • insulin tolerance test
    Àν¶¸°³»¼º½ÃÇè.
  • lactose tolerance test
    ¶ôÅä¿À½º³»¼º½ÃÇè (¡­Ò±àõãËúÐ).
  • lactose tolerance test
    ¶ôÅä¿À½º³»¼º½ÃÇè
  • levulose tolerance test
    °ú´çºÎÇϽÃÇè.
  • low dose tolerance
    ¼Ò·®¸é¿ª°ü¿ë(ËÛËâËÎËçË´Ëí).
  • low dose tolerance
    ¼Ò·®¸é¿ª°ü¿ë(á´åÖØóæ¹Î°é»).
  • low-zone tolerance
    ¹Ì·®¸é¿ª°ü¿ë (Ç׿ø)
  • maximum tolerance dose
    ÃÖ´ë°ßµõ¼±·®
  • maximum tolerance dose =MTD
    ÃÖ´ë³»¿ë·®(õÌÓÞÒ±éÄåÖ).
  • median tolerance limit
    ¹Ý¼ö»ýÁ¸ÇѰè³óµµ (Úââ¦ßæðíùÚÍ£ÒØöô).
  • median tolerance limit
    ¹Ý¼ö»ýÁ¸ÇѰè³óµµ(Úââ¦ßæðíùÚÍ£ÒØöô).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • NP antigen
    NPÇ׿ø(ù÷ê«)
  • O antigen
    O Ç׿ø(ù÷ê«)
  • P antigen
    P
  • particulate antigen
    ÀÔÀÚ Ç׿ø(Ø£í­ù÷ê«)
  • penton antigen
    ÆæÅæ Ç׿ø(ù÷ê«)
  • protective antigen
    º¸È£ Ç׿ø(ÜÁûÞù÷ê«)
  • R antigen
    R Ç׿ø(ù÷ê«)
  • S antigen
    S Ç׿ø(ù÷ê«)
  • SH-antigen
    SH-Ç׿ø(ù÷ê«)
  • soluble antigen
    °¡¿ëÇ׿ø(ʦéÁù÷ê«)
  • surface antigen
    Ç¥¸éÇ׿ø (øúØüù÷ê«)
  • t antigen
    t Ç׿ø(ù÷ê«)
  • T antigen
    T Ç׿ø(ù÷ê«)
  • Thy-1-antigen
    Thy-1-Ç׿ø(ù÷ê«)
  • tissue polypeptide antigen
    Á¶Á÷(ðÚòÄ)Æú¸®ÆéŸÀ̵å Ç׿ø (ù÷ê«)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
HTA heterophil transplantation antigen; human thymocyte antigen; hydroxytryptamine; hypophysiotropic are...
LA lactic acid; large amount; laser angioplasty; late abortion; late antigen; latex agglutination; left...
LFA left femoral artery; left frontal craniotomy; left fronto-anterior [fetal position]; leukocyte funct...
MSA major serologic antigen; male-specific antigen; mannitol salt agar; Medical Services Administration;...
PA panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
OGTT Oral glucose tolerance
OGTT Oral glucose tolerance testing
ATR acid tolerance response
FSIGT frequently sampled intravenous glucose tolerance test
FSIVGTT frequently sampled intravenous glucose tolerance test
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • dander antigen
    Àμ³ Ç׿ø
    ÇǺÎÀÇ Ç¥¸éÀ¸·ÎºÎÅÍ ²÷ÀÓ¾øÀÌ »êÆ÷µÇ°í ÀÖ´Â ¹°ÁúÀÇ È¥ÇÕ¹°. ¹Ú¸®µÈ »óÇÇ ¼¼¹Î, ÅÐÀÇ ´ÜÆí, ÇǺÎÀÇ Áö¹æ µîÀÌ Æ÷ÇԵǴµ¥ ƯÈ÷ Àμ³ÀÌ Áß¿äÇÏ´Ù. ¾ÆÅäÇǰ¡ ÀÖ´Â »ç¶÷¿¡¼­´Â Áï½ÃÇü °ú¹ÎÁõÀÇ ¿øÀÎÀÌ µÇ´Â ¼ö°¡ ÀÖ´Ù.
  • determinant antigen
    Ç׿ø °áÁ¤±º, °áÁ¤ Ç׿ø
    ¸é¿ªÇÐÀû ƯÀ̼ºÀ» °áÁ¤Çϴ ƯÁ¤ÀÇ È­ÇÐÀûÀÎ ºÐÀÚ±º.
  • diego antigen
    µð¿¡°í Ç׿ø
  • differentiation antigen
    ºÐÈ­ Ç׿ø
    ¼¼Æ÷°¡ ºÐÈ­ÇØ °¡´Âµ¥ À־ Ç¥ÇöµÇ´Â ¼¼Æ÷¸· »óÀÇ Ç׿ø. T ¼¼Æ÷¿¡¼­´Â B ¼¼Æ÷·ÎºÎÅÍ ±¸º°ÇÏ´Â ºÐÈ­ Ç׿øÀº mouse »çÀÌ¿¡¼­ ¼¼Æ÷¸¦ Åõ¿©ÇÏ¿© ¸¸µé¾îÁø µ¿Á¾ Ç×Ç÷û¿¡ ÀÇÇÏ¿© °ËÃâµÇ´Â Ç׿ø
  • DR antigen
    DR Ç׿ø
    HLA-D ¿µ¿ª À¯ÀüÀÚÀÇ Áö¹è¸¦ ¹Þ´Â Ç׿øÀ̸ç, ÁÖ·Î B ¼¼Æ÷ ¹× macro
  • endogenous antigen
    ³»ºÎ Ç׿ø
    µ¿¹°ÀÇ Ã¼³»¿¡ Á¸ÀçÇÏ´Â °Íµé·Î¼­ µ¿¹°ÀÇ Á¶Á÷, ¼¼Æ÷ÀÇ ÀϺΠ±¸¼º ¼ººÐ µîÀÌ ¿©±â¿¡ ¼ÓÇÑ´Ù.
  • ensitization 1. administration of antigen to induce a primary immune response; priming; immunization. 2. exposure to allergen that results in the development of hypersensitivity. 3. the coating of erythrocytes with antibody so that they are subject to lys
    ³»¹ø
    ƯÈ÷ ¾È°Ë ¿¬ÀÇ.
  • fetal antigen
    ÅÂ¾Æ Ç׿ø
    Á¾¾ç °ü·Ã Ç׿øÀÇ ÀÏÁ¾, Å»ý±â Á¶Á÷¿¡¼­´Â ÀÎÁ¤µÇÁö¸¸, Á¤»óÀûÀÎ ºÐÈ­¸¦ ¹âÀº Á¶Á÷¿¡¼­´Â ÀÎÁ¤µÇÁö ¾Ê°Å³ª ±ØÈ÷ ¹Ì·® Á¸ÀçÇϰųª ÇÑ´Ù.
  • H antigen
    H Ç׿ø
    1. ¿îµ¿¼º ¼¼±ÕÀÇ Æí¸ð Ç׿ø 2. H-¹°Áú.
  • H-2 antigen
    H-2 Ç׿ø
  • heterologous antigen
    ÀÌÁ¾ Ç׿ø
  • HL-A type antigen
    ¿¡ÀÌÄ¡¿¤¿¡ÀÌ Ç׿ø
    »ç¶÷ÀÇ ÀûÇ÷±¸ ÀÌ¿ÜÀÇ ¸ðµç ¼¼Æ÷°¡ °¡Áö°í ÀÖ´Â Ç׿ø. »ç¶÷ ¹éÇ÷±¸ Ç׿øÀ̶ó°íµµ ÇÑ´Ù. H´Â »ç¶÷
  • homologous antigen
    »óµ¿ Ç׿ø
  • human histocompatibility antigen
    ÀÎü Á¶Á÷ ÀûÇÕ Ç׿ø
  • human leukocyte antigen-B27
    ÀÎü ¹éÇ÷±¸ Ç×ü-B27
    º¸Åë °­Á÷¼º ôÃß¿° ȯÀÚ¿¡¼­ ³ªÅ¸³ª´Â À¯Àü Ç¥½ÃÀÚ.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
antigen-sensitive cell A small lymphocyte that, although not itself an immunologically activated cell, responds to antigenic (immunogenic) stimulus by a process of division and differentiation that results in the production of immunologically activated cells.
Synonym: antigen-responsive cell.
(05 Mar 2000)
antigen shift Abrupt change in antigens expressed by a species or variety of organisms. Usually seen in microorganisms where the change may allow escape from immune recognition. Antigenic drift is a more gradual change.
See: antigenic variation.
(18 Nov 1997)
antigen unit The smallest amount of antigen that, in the presence of specific antiserum, will fix 1 complement unit.
(05 Mar 2000)
aspergillus antigen skin test <investigation> An antigen, prepared from aspergillus, is injected into the skin. In 48 to 72 hours the site is read as positive or negative. A positive skin test (inflammation at the test site) indicates prior exposure to aspergillus and therefore a risk for developing aspergillosis.
(27 Sep 1997)
Au antigen Auberger blood group
Aus antigen <virology> An envelope antigen now known as HBsAg of Hepatitis B virus. Appearance of the antigen in serum is associated with a phase of high infectivity.
(18 Nov 1997)
Australia antigen <virology> An envelope antigen now known as HBsAg of Hepatitis B virus. Appearance of the antigen in serum is associated with a phase of high infectivity.
(18 Nov 1997)
B-cell antigen receptors In the primary immune response immunoglobulin D and monomeric immunoglobulin M are the B-cell antigen receptors. On memory B-cells, other immunoglobulin molecules can serve as antigen receptors.
(05 Mar 2000)
becker antigen bea antigen
blood group antigen <haematology, immunology> The set of cell surface antigens found chiefly, but not solely, on blood cells.
More than fifteen different blood group systems are recognised in humans. There may be naturally occurring antibodies without immunisation, especially in the case of the ABO system and matching blood groups is important for safe transfusion.
In most cases the antigenic determinant resides in the carbohydrate chains of membrane glycoproteins or glycolipids.
See: Rhesus, Duffy, Kell, Lewis and MN.
(25 Jun 1999)
cancer antigen 125 test Test for cell-surface antigen found on derivatives of coelomic epithelium. Elevated levels of this antigen are associated with ovarian malignancy and benign pelvic disease such as endometriosis.
(05 Mar 2000)
capsular antigen That found only in the capsules of certain microorganisms; e.g., the specific polysaccharides of various types of pneumococci.
(05 Mar 2000)
carcinoembryonic antigen <tumour marker> Antigen found in blood of patients suffering from cancer of colon and some other diseases, that is otherwise normally found in foetal gut tissue.
(19 Jan 1998)
macrophage-1 antigen An adhesion-promoting leukocyte surface membrane heterodimer. The alpha subunit consists of the CD11b antigen and the beta subunit of the CD18 antigen (antigens, CD18). The antigen, which is an integrin, functions both as a receptor for complement 3 and in cell-cell and cell-substrate adhesive interactions.
(12 Dec 1998)
V antigen Viral antigen that is intimately associated with the virus particle, is protein in nature, has multiple antigenicities, and is strain-specific; antibody to such antigen is demonstrable as protective or neutralizing antibody.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á